Anabolic Resistance, Sarcopenia
Conditions
Keywords
Resistance training, Aging, Resveratrol, Sarcopenia, Extracellular Vesicles, MicroRNAs
Brief summary
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.
Detailed description
After screening and providing informed consent, participants (healthy older adults, age 60+, minimally active) will be familiarized with the procedures and undergo pre-testing. After pre-testing, participants will be assigned to supplement with resveratrol or placebo (double-blinded) daily while undergoing a strength training intervention. Strength training will be performed 3x/week for two 6-week blocks, and each visit will be supervised by a member of the study team. An additional week of testing will follow each of the two 6-week blocks.
Interventions
BEHAVIORALResistance training
After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.
DIETARY_SUPPLEMENTResveratrol 500 mg oral once daily.
Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
DIETARY_SUPPLEMENTPlacebo
Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
Sponsors
Texas Tech University
National Strength and Conditioning Association
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
After pre-testing, participants will be randomized to supplement with resveratrol (500 mg) or placebo for 14 weeks. All participants will complete two 6-week blocks of supervised strength training (full body, 3 days/week); each block will be followed by one week of testing.
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 60+ * Minimally active (less than 1 hour of structured exercise/week other than walking) * No resistance training for the previous 6 months * Not currently taking resveratrol supplements * Stable medication, supplement, dietary, and physical activity regimens for the previous 3 months and no plans to change throughout the study period * Body mass at least 110 lbs
Exclusion criteria
* Medical complications that could increase risk during exercise (e.g., cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes, orthopedic contraindication to exercise, kidney disease, etc.) * Cannabis or nicotine use * Consume more than 7 alcohol-containing beverages per week
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Circulating extracellular vesicle microRNA profile | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Circulating extracellular vesicles will be isolated from plasma and their microRNA cargo will be sequenced. |
| Muscle torque | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Participants will be instructed to try and straighten their leg, against resistance, as forcefully as possible and maximal torque of the quadriceps assessed using a dynamometer. |
| Muscle fatigability | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Participants will perform 32 repetitions of knee extensions on a dynamometer and the change in torque from the beginning to the end will be used to indicate fatigability. |
| Muscle strength | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Participants will perform submaximal testing to assess strength on key exercises included in the strength training protocol. |
| Appendicular skeletal muscle mass index | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Assessed using dual-energy x-ray absorptiometry (DEXA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Waist-to-hip ratio | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Waist and hip circumferences measured using measuring tape |
| Vascular function | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Flow-mediated dilation |
| Cognitive function | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) |
| Grip strength | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Handgrip dynamometry |
| Lower body strength/endurance | During pre-, mid-, and post-testing (each separated by about 6 weeks) | Chair stand test (30 seconds) |
| Gait speed | During pre-, mid-, and post-testing (each separated by about 6 weeks) | 4-m walk test |
Countries
United States
Contacts
CONTACTDanielle E Levitt, PhD
CONTACTJacob A Mota, PhD
PRINCIPAL_INVESTIGATORDanielle E Levitt, PhD
Texas Tech University
Outcome results
None listed